

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3a - Summary of and Statistical Analysis for Presence of Cough at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	40 ( 37.4%)	43 ( 41.0%)	83 ( 39.2%)
	Yes	67 ( 62.6%)	62 ( 59.0%)	129 ( 60.8%)
DAY 2	n	106	105	211
	No	44 ( 41.5%)	43 ( 41.0%)	87 ( 41.2%)
	Yes	62 ( 58.5%)	62 ( 59.0%)	124 ( 58.8%)
DAY 3	n	103	102	205
	No	49 ( 47.6%)	48 ( 47.1%)	97 ( 47.3%)
	Yes	54 ( 52.4%)	54 ( 52.9%)	108 ( 52.7%)
DAY 4	n	103	96	199
	No	46 ( 44.7%)	47 ( 49.0%)	93 ( 46.7%)
	Yes	57 ( 55.3%)	49 ( 51.0%)	106 ( 53.3%)
DAY 5	n	102	95	197
	No	53 ( 52.0%)	52 ( 54.7%)	105 ( 53.3%)
	Yes	49 ( 48.0%)	43 ( 45.3%)	92 ( 46.7%)
DAY 6	n	103	92	195
	No	55 ( 53.4%)	54 ( 58.7%)	109 ( 55.9%)
	Yes	48 ( 46.6%)	38 ( 41.3%)	86 ( 44.1%)
DAY 7	n	102	91	193
	No	57 ( 55.9%)	54 ( 59.3%)	111 ( 57.5%)
	Yes	45 ( 44.1%)	37 ( 40.7%)	82 ( 42.5%)
DAY 8	n	101	90	191
	No	64 ( 63.4%)	58 ( 64.4%)	122 ( 63.9%)
	Yes	37 ( 36.6%)	32 ( 35.6%)	69 ( 36.1%)
DAY 9	n	100	89	189
	No	61 ( 61.0%)	62 ( 69.7%)	123 ( 65.1%)
	Yes	39 ( 39.0%)	27 ( 30.3%)	66 ( 34.9%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
 2.2 - Secondary Analysis

Table 2.2.3a - Summary of and Statistical Analysis for Presence of Cough at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	65 ( 65.0%)	64 ( 71.1%)	129 ( 67.9%)
	Yes	35 ( 35.0%)	26 ( 28.9%)	61 ( 32.1%)
DAY 11	n	98	86	184
	No	66 ( 67.3%)	64 ( 74.4%)	130 ( 70.7%)
	Yes	32 ( 32.7%)	22 ( 25.6%)	54 ( 29.3%)
DAY 12	n	99	85	184
	No	68 ( 68.7%)	62 ( 72.9%)	130 ( 70.7%)
	Yes	31 ( 31.3%)	23 ( 27.1%)	54 ( 29.3%)
DAY 13	n	98	83	181
	No	67 ( 68.4%)	64 ( 77.1%)	131 ( 72.4%)
	Yes	31 ( 31.6%)	19 ( 22.9%)	50 ( 27.6%)
DAY 14	n	95	79	174
	No	66 ( 69.5%)	58 ( 73.4%)	124 ( 71.3%)
	Yes	29 ( 30.5%)	21 ( 26.6%)	50 ( 28.7%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3a – Summary of and Statistical Analysis for Presence of Cough at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.02 (0.59; 1.77)	0.9416
Hesperidin vs Placebo at Day 7	0.87 (0.49; 1.55)	0.6296
Hesperidin vs Placebo at Day 10	0.75 (0.41; 1.40)	0.3711
Hesperidin vs Placebo at Day 14	0.82 (0.42; 1.61)	0.5696

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3b - Summary of and Statistical Analysis for Presence of Fever at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	105	102	207
	No	100 ( 95.2%)	99 ( 97.1%)	199 ( 96.1%)
	Yes	5 ( 4.8%)	3 ( 2.9%)	8 ( 3.9%)
DAY 2	n	105	103	208
	No	101 ( 96.2%)	100 ( 97.1%)	201 ( 96.6%)
	Yes	4 ( 3.8%)	3 ( 2.9%)	7 ( 3.4%)
DAY 3	n	102	101	203
	No	96 ( 94.1%)	96 ( 95.0%)	192 ( 94.6%)
	Yes	6 ( 5.9%)	5 ( 5.0%)	11 ( 5.4%)
DAY 4	n	102	95	197
	No	99 ( 97.1%)	92 ( 96.8%)	191 ( 97.0%)
	Yes	3 ( 2.9%)	3 ( 3.2%)	6 ( 3.0%)
DAY 5	n	102	94	196
	No	98 ( 96.1%)	89 ( 94.7%)	187 ( 95.4%)
	Yes	4 ( 3.9%)	5 ( 5.3%)	9 ( 4.6%)
DAY 6	n	102	91	193
	No	99 ( 97.1%)	88 ( 96.7%)	187 ( 96.9%)
	Yes	3 ( 2.9%)	3 ( 3.3%)	6 ( 3.1%)
DAY 7	n	101	90	191
	No	97 ( 96.0%)	87 ( 96.7%)	184 ( 96.3%)
	Yes	4 ( 4.0%)	3 ( 3.3%)	7 ( 3.7%)
DAY 8	n	100	90	190
	No	97 ( 97.0%)	87 ( 96.7%)	184 ( 96.8%)
	Yes	3 ( 3.0%)	3 ( 3.3%)	6 ( 3.2%)
DAY 9	n	99	89	188
	No	98 ( 99.0%)	87 ( 97.8%)	185 ( 98.4%)
	Yes	1 ( 1.0%)	2 ( 2.2%)	3 ( 1.6%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
 2.2 - Secondary Analysis

Table 2.2.3b - Summary of and Statistical Analysis for Presence of Fever at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	99	90	189
	No	97 ( 98.0%)	87 ( 96.7%)	184 ( 97.4%)
	Yes	2 ( 2.0%)	3 ( 3.3%)	5 ( 2.6%)
DAY 11	n	97	86	183
	No	96 ( 99.0%)	84 ( 97.7%)	180 ( 98.4%)
	Yes	1 ( 1.0%)	2 ( 2.3%)	3 ( 1.6%)
DAY 12	n	98	85	183
	No	97 ( 99.0%)	84 ( 98.8%)	181 ( 98.9%)
	Yes	1 ( 1.0%)	1 ( 1.2%)	2 ( 1.1%)
DAY 13	n	97	83	180
	No	96 ( 99.0%)	82 ( 98.8%)	178 ( 98.9%)
	Yes	1 ( 1.0%)	1 ( 1.2%)	2 ( 1.1%)
DAY 14	n	94	79	173
	No	93 ( 98.9%)	79 (100.0%)	172 ( 99.4%)
	Yes	1 ( 1.1%)	0 ( 0.0%)	1 ( 0.6%)

Note:  
 Comparisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3b – Summary of and Statistical Analysis for Presence of Fever at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	0.83 (0.26; 2.67)	0.7583
Hesperidin vs Placebo at Day 7	0.84 (0.20; 3.58)	0.8091
Hesperidin vs Placebo at Day 10	1.67 (0.30; 9.42)	0.5591
Hesperidin vs Placebo at Day 14	0.00 (0.00; ND)	0.9983

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3c - Summary of and Statistical Analysis for Presence of Feverish or Chills at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	75 ( 70.1%)	69 ( 65.7%)	144 ( 67.9%)
	Yes	32 ( 29.9%)	36 ( 34.3%)	68 ( 32.1%)
DAY 2	n	106	105	211
	No	82 ( 77.4%)	70 ( 66.7%)	152 ( 72.0%)
	Yes	24 ( 22.6%)	35 ( 33.3%)	59 ( 28.0%)
DAY 3	n	103	102	205
	No	82 ( 79.6%)	78 ( 76.5%)	160 ( 78.0%)
	Yes	21 ( 20.4%)	24 ( 23.5%)	45 ( 22.0%)
DAY 4	n	103	96	199
	No	89 ( 86.4%)	77 ( 80.2%)	166 ( 83.4%)
	Yes	14 ( 13.6%)	19 ( 19.8%)	33 ( 16.6%)
DAY 5	n	102	95	197
	No	89 ( 87.3%)	79 ( 83.2%)	168 ( 85.3%)
	Yes	13 ( 12.7%)	16 ( 16.8%)	29 ( 14.7%)
DAY 6	n	103	92	195
	No	93 ( 90.3%)	79 ( 85.9%)	172 ( 88.2%)
	Yes	10 ( 9.7%)	13 ( 14.1%)	23 ( 11.8%)
DAY 7	n	102	91	193
	No	92 ( 90.2%)	81 ( 89.0%)	173 ( 89.6%)
	Yes	10 ( 9.8%)	10 ( 11.0%)	20 ( 10.4%)
DAY 8	n	101	90	191
	No	91 ( 90.1%)	82 ( 91.1%)	173 ( 90.6%)
	Yes	10 ( 9.9%)	8 ( 8.9%)	18 ( 9.4%)
DAY 9	n	100	89	189
	No	93 ( 93.0%)	85 ( 95.5%)	178 ( 94.2%)
	Yes	7 ( 7.0%)	4 ( 4.5%)	11 ( 5.8%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
 2.2 - Secondary Analysis

Table 2.2.3c - Summary of and Statistical Analysis for Presence of Feverish or Chills at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	94 ( 94.0%)	86 ( 95.6%)	180 ( 94.7%)
	Yes	6 ( 6.0%)	4 ( 4.4%)	10 ( 5.3%)
DAY 11	n	98	86	184
	No	93 ( 94.9%)	83 ( 96.5%)	176 ( 95.7%)
	Yes	5 ( 5.1%)	3 ( 3.5%)	8 ( 4.3%)
DAY 12	n	99	85	184
	No	95 ( 96.0%)	83 ( 97.6%)	178 ( 96.7%)
	Yes	4 ( 4.0%)	2 ( 2.4%)	6 ( 3.3%)
DAY 13	n	98	83	181
	No	96 ( 98.0%)	82 ( 98.8%)	178 ( 98.3%)
	Yes	2 ( 2.0%)	1 ( 1.2%)	3 ( 1.7%)
DAY 14	n	95	79	174
	No	92 ( 96.8%)	78 ( 98.7%)	170 ( 97.7%)
	Yes	3 ( 3.2%)	1 ( 1.3%)	4 ( 2.3%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.



2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3c – Summary of and Statistical Analysis for Presence of Feverish or Chills at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.20 (0.62; 2.34)	0.5894
Hesperidin vs Placebo at Day 7	1.14 (0.45; 2.89)	0.7887
Hesperidin vs Placebo at Day 10	0.73 (0.20; 2.70)	0.6348
Hesperidin vs Placebo at Day 14	0.39 (0.04; 3.92)	0.4257

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3d - Summary of and Statistical Analysis for Presence of Sore Throat at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	66 ( 61.7%)	62 ( 59.0%)	128 ( 60.4%)
	Yes	41 ( 38.3%)	43 ( 41.0%)	84 ( 39.6%)
DAY 2	n	106	105	211
	No	71 ( 67.0%)	65 ( 61.9%)	136 ( 64.5%)
	Yes	35 ( 33.0%)	40 ( 38.1%)	75 ( 35.5%)
DAY 3	n	103	102	205
	No	80 ( 77.7%)	69 ( 67.6%)	149 ( 72.7%)
	Yes	23 ( 22.3%)	33 ( 32.4%)	56 ( 27.3%)
DAY 4	n	103	96	199
	No	80 ( 77.7%)	69 ( 71.9%)	149 ( 74.9%)
	Yes	23 ( 22.3%)	27 ( 28.1%)	50 ( 25.1%)
DAY 5	n	102	95	197
	No	79 ( 77.5%)	70 ( 73.7%)	149 ( 75.6%)
	Yes	23 ( 22.5%)	25 ( 26.3%)	48 ( 24.4%)
DAY 6	n	103	92	195
	No	86 ( 83.5%)	76 ( 82.6%)	162 ( 83.1%)
	Yes	17 ( 16.5%)	16 ( 17.4%)	33 ( 16.9%)
DAY 7	n	102	91	193
	No	89 ( 87.3%)	74 ( 81.3%)	163 ( 84.5%)
	Yes	13 ( 12.7%)	17 ( 18.7%)	30 ( 15.5%)
DAY 8	n	101	90	191
	No	88 ( 87.1%)	78 ( 86.7%)	166 ( 86.9%)
	Yes	13 ( 12.9%)	12 ( 13.3%)	25 ( 13.1%)
DAY 9	n	100	89	189
	No	87 ( 87.0%)	84 ( 94.4%)	171 ( 90.5%)
	Yes	13 ( 13.0%)	5 ( 5.6%)	18 ( 9.5%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3d - Summary of and Statistical Analysis for Presence of Sore Throat at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	92 ( 92.0%)	84 ( 93.3%)	176 ( 92.6%)
	Yes	8 ( 8.0%)	6 ( 6.7%)	14 ( 7.4%)
DAY 11	n	98	86	184
	No	90 ( 91.8%)	82 ( 95.3%)	172 ( 93.5%)
	Yes	8 ( 8.2%)	4 ( 4.7%)	12 ( 6.5%)
DAY 12	n	99	85	184
	No	93 ( 93.9%)	81 ( 95.3%)	174 ( 94.6%)
	Yes	6 ( 6.1%)	4 ( 4.7%)	10 ( 5.4%)
DAY 13	n	98	83	181
	No	93 ( 94.9%)	81 ( 97.6%)	174 ( 96.1%)
	Yes	5 ( 5.1%)	2 ( 2.4%)	7 ( 3.9%)
DAY 14	n	95	79	174
	No	91 ( 95.8%)	76 ( 96.2%)	167 ( 96.0%)
	Yes	4 ( 4.2%)	3 ( 3.8%)	7 ( 4.0%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3d – Summary of and Statistical Analysis for Presence of Sore Throat at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.66 (0.89; 3.11)	0.1113
Hesperidin vs Placebo at Day 7	1.57 (0.71; 3.47)	0.2613
Hesperidin vs Placebo at Day 10	0.82 (0.27; 2.49)	0.7273
Hesperidin vs Placebo at Day 14	0.90 (0.19; 4.19)	0.8909

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3e - Summary of and Statistical Analysis for Presence of Runny Nose at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	57 ( 53.3%)	52 ( 49.5%)	109 ( 51.4%)
	Yes	50 ( 46.7%)	53 ( 50.5%)	103 ( 48.6%)
DAY 2	n	106	105	211
	No	59 ( 55.7%)	50 ( 47.6%)	109 ( 51.7%)
	Yes	47 ( 44.3%)	55 ( 52.4%)	102 ( 48.3%)
DAY 3	n	103	102	205
	No	65 ( 63.1%)	54 ( 52.9%)	119 ( 58.0%)
	Yes	38 ( 36.9%)	48 ( 47.1%)	86 ( 42.0%)
DAY 4	n	103	96	199
	No	68 ( 66.0%)	56 ( 58.3%)	124 ( 62.3%)
	Yes	35 ( 34.0%)	40 ( 41.7%)	75 ( 37.7%)
DAY 5	n	102	95	197
	No	70 ( 68.6%)	59 ( 62.1%)	129 ( 65.5%)
	Yes	32 ( 31.4%)	36 ( 37.9%)	68 ( 34.5%)
DAY 6	n	103	92	195
	No	74 ( 71.8%)	64 ( 69.6%)	138 ( 70.8%)
	Yes	29 ( 28.2%)	28 ( 30.4%)	57 ( 29.2%)
DAY 7	n	102	91	193
	No	80 ( 78.4%)	66 ( 72.5%)	146 ( 75.6%)
	Yes	22 ( 21.6%)	25 ( 27.5%)	47 ( 24.4%)
DAY 8	n	101	90	191
	No	78 ( 77.2%)	66 ( 73.3%)	144 ( 75.4%)
	Yes	23 ( 22.8%)	24 ( 26.7%)	47 ( 24.6%)
DAY 9	n	100	89	189
	No	78 ( 78.0%)	68 ( 76.4%)	146 ( 77.2%)
	Yes	22 ( 22.0%)	21 ( 23.6%)	43 ( 22.8%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3e - Summary of and Statistical Analysis for Presence of Runny Nose at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	83 ( 83.0%)	72 ( 80.0%)	155 ( 81.6%)
	Yes	17 ( 17.0%)	18 ( 20.0%)	35 ( 18.4%)
DAY 11	n	98	86	184
	No	83 ( 84.7%)	71 ( 82.6%)	154 ( 83.7%)
	Yes	15 ( 15.3%)	15 ( 17.4%)	30 ( 16.3%)
DAY 12	n	99	85	184
	No	86 ( 86.9%)	72 ( 84.7%)	158 ( 85.9%)
	Yes	13 ( 13.1%)	13 ( 15.3%)	26 ( 14.1%)
DAY 13	n	98	83	181
	No	86 ( 87.8%)	69 ( 83.1%)	155 ( 85.6%)
	Yes	12 ( 12.2%)	14 ( 16.9%)	26 ( 14.4%)
DAY 14	n	95	79	174
	No	85 ( 89.5%)	67 ( 84.8%)	152 ( 87.4%)
	Yes	10 ( 10.5%)	12 ( 15.2%)	22 ( 12.6%)

Note:  
Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3e – Summary of and Statistical Analysis for Presence of Runny Nose at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.52 (0.87; 2.67)	0.1438
Hesperidin vs Placebo at Day 7	1.38 (0.71; 2.68)	0.3440
Hesperidin vs Placebo at Day 10	1.22 (0.58; 2.56)	0.5968
Hesperidin vs Placebo at Day 14	1.52 (0.62; 3.76)	0.3620

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3f - Summary of and Statistical Analysis for Presence of Shortness of Breath/Difficulty Breathing at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	65 ( 60.7%)	54 ( 51.4%)	119 ( 56.1%)
	Yes	42 ( 39.3%)	51 ( 48.6%)	93 ( 43.9%)
DAY 2	n	106	105	211
	No	62 ( 58.5%)	52 ( 49.5%)	114 ( 54.0%)
	Yes	44 ( 41.5%)	53 ( 50.5%)	97 ( 46.0%)
DAY 3	n	103	102	205
	No	68 ( 66.0%)	56 ( 54.9%)	124 ( 60.5%)
	Yes	35 ( 34.0%)	46 ( 45.1%)	81 ( 39.5%)
DAY 4	n	103	96	199
	No	68 ( 66.0%)	58 ( 60.4%)	126 ( 63.3%)
	Yes	35 ( 34.0%)	38 ( 39.6%)	73 ( 36.7%)
DAY 5	n	102	95	197
	No	71 ( 69.6%)	56 ( 58.9%)	127 ( 64.5%)
	Yes	31 ( 30.4%)	39 ( 41.1%)	70 ( 35.5%)
DAY 6	n	103	92	195
	No	76 ( 73.8%)	56 ( 60.9%)	132 ( 67.7%)
	Yes	27 ( 26.2%)	36 ( 39.1%)	63 ( 32.3%)
DAY 7	n	102	91	193
	No	72 ( 70.6%)	63 ( 69.2%)	135 ( 69.9%)
	Yes	30 ( 29.4%)	28 ( 30.8%)	58 ( 30.1%)
DAY 8	n	101	90	191
	No	73 ( 72.3%)	63 ( 70.0%)	136 ( 71.2%)
	Yes	28 ( 27.7%)	27 ( 30.0%)	55 ( 28.8%)
DAY 9	n	100	89	189
	No	79 ( 79.0%)	64 ( 71.9%)	143 ( 75.7%)
	Yes	21 ( 21.0%)	25 ( 28.1%)	46 ( 24.3%)

Note:

Comparisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.



2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3f - Summary of and Statistical Analysis for Presence of Shortness of Breath/Difficulty Breathing at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	82 ( 82.0%)	71 ( 78.9%)	153 ( 80.5%)
	Yes	18 ( 18.0%)	19 ( 21.1%)	37 ( 19.5%)
DAY 11	n	98	86	184
	No	80 ( 81.6%)	70 ( 81.4%)	150 ( 81.5%)
	Yes	18 ( 18.4%)	16 ( 18.6%)	34 ( 18.5%)
DAY 12	n	99	85	184
	No	84 ( 84.8%)	73 ( 85.9%)	157 ( 85.3%)
	Yes	15 ( 15.2%)	12 ( 14.1%)	27 ( 14.7%)
DAY 13	n	98	83	181
	No	83 ( 84.7%)	70 ( 84.3%)	153 ( 84.5%)
	Yes	15 ( 15.3%)	13 ( 15.7%)	28 ( 15.5%)
DAY 14	n	95	79	174
	No	82 ( 86.3%)	65 ( 82.3%)	147 ( 84.5%)
	Yes	13 ( 13.7%)	14 ( 17.7%)	27 ( 15.5%)

Note:  
Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3f – Summary of and Statistical Analysis for Presence of Shortness of Breath/Difficulty Breathing at Day 1 to 14, ITT Population  
 (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.60 (0.90; 2.82)	0.1068
Hesperidin vs Placebo at Day 7	1.07 (0.57; 1.98)	0.8382
Hesperidin vs Placebo at Day 10	1.22 (0.59; 2.51)	0.5912
Hesperidin vs Placebo at Day 14	1.36 (0.59; 3.11)	0.4677

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3g - Summary of and Statistical Analysis for Presence of Nausea/Vomiting at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	95 ( 88.8%)	83 ( 79.0%)	178 ( 84.0%)
	Yes	12 ( 11.2%)	22 ( 21.0%)	34 ( 16.0%)
DAY 2	n	106	105	211
	No	91 ( 85.8%)	83 ( 79.0%)	174 ( 82.5%)
	Yes	15 ( 14.2%)	22 ( 21.0%)	37 ( 17.5%)
DAY 3	n	103	102	205
	No	91 ( 88.3%)	81 ( 79.4%)	172 ( 83.9%)
	Yes	12 ( 11.7%)	21 ( 20.6%)	33 ( 16.1%)
DAY 4	n	103	96	199
	No	94 ( 91.3%)	81 ( 84.4%)	175 ( 87.9%)
	Yes	9 ( 8.7%)	15 ( 15.6%)	24 ( 12.1%)
DAY 5	n	102	95	197
	No	95 ( 93.1%)	80 ( 84.2%)	175 ( 88.8%)
	Yes	7 ( 6.9%)	15 ( 15.8%)	22 ( 11.2%)
DAY 6	n	103	92	195
	No	97 ( 94.2%)	79 ( 85.9%)	176 ( 90.3%)
	Yes	6 ( 5.8%)	13 ( 14.1%)	19 ( 9.7%)
DAY 7	n	102	91	193
	No	91 ( 89.2%)	82 ( 90.1%)	173 ( 89.6%)
	Yes	11 ( 10.8%)	9 ( 9.9%)	20 ( 10.4%)
DAY 8	n	101	90	191
	No	95 ( 94.1%)	81 ( 90.0%)	176 ( 92.1%)
	Yes	6 ( 5.9%)	9 ( 10.0%)	15 ( 7.9%)
DAY 9	n	100	89	189
	No	96 ( 96.0%)	81 ( 91.0%)	177 ( 93.7%)
	Yes	4 ( 4.0%)	8 ( 9.0%)	12 ( 6.3%)

Note:

Comparisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3g - Summary of and Statistical Analysis for Presence of Nausea/Vomiting at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	95 ( 95.0%)	84 ( 93.3%)	179 ( 94.2%)
	Yes	5 ( 5.0%)	6 ( 6.7%)	11 ( 5.8%)
DAY 11	n	98	86	184
	No	93 ( 94.9%)	82 ( 95.3%)	175 ( 95.1%)
	Yes	5 ( 5.1%)	4 ( 4.7%)	9 ( 4.9%)
DAY 12	n	99	85	184
	No	96 ( 97.0%)	83 ( 97.6%)	179 ( 97.3%)
	Yes	3 ( 3.0%)	2 ( 2.4%)	5 ( 2.7%)
DAY 13	n	98	83	181
	No	94 ( 95.9%)	82 ( 98.8%)	176 ( 97.2%)
	Yes	4 ( 4.1%)	1 ( 1.2%)	5 ( 2.8%)
DAY 14	n	95	79	174
	No	93 ( 97.9%)	77 ( 97.5%)	170 ( 97.7%)
	Yes	2 ( 2.1%)	2 ( 2.5%)	4 ( 2.3%)

Note:  
Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3g – Summary of and Statistical Analysis for Presence of Nausea/Vomiting at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.97 (0.91; 4.27)	0.0875
Hesperidin vs Placebo at Day 7	0.91 (0.36; 2.32)	0.8397
Hesperidin vs Placebo at Day 10	1.36 (0.40; 4.65)	0.6265
Hesperidin vs Placebo at Day 14	1.21 (0.16; 8.91)	0.8528

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3h - Summary of and Statistical Analysis for Presence of Headache at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	39 ( 36.4%)	38 ( 36.2%)	77 ( 36.3%)
	Yes	68 ( 63.6%)	67 ( 63.8%)	135 ( 63.7%)
DAY 2	n	106	105	211
	No	54 ( 50.9%)	49 ( 46.7%)	103 ( 48.8%)
	Yes	52 ( 49.1%)	56 ( 53.3%)	108 ( 51.2%)
DAY 3	n	103	102	205
	No	62 ( 60.2%)	54 ( 52.9%)	116 ( 56.6%)
	Yes	41 ( 39.8%)	48 ( 47.1%)	89 ( 43.4%)
DAY 4	n	103	96	199
	No	68 ( 66.0%)	53 ( 55.2%)	121 ( 60.8%)
	Yes	35 ( 34.0%)	43 ( 44.8%)	78 ( 39.2%)
DAY 5	n	102	95	197
	No	66 ( 64.7%)	58 ( 61.1%)	124 ( 62.9%)
	Yes	36 ( 35.3%)	37 ( 38.9%)	73 ( 37.1%)
DAY 6	n	103	92	195
	No	73 ( 70.9%)	58 ( 63.0%)	131 ( 67.2%)
	Yes	30 ( 29.1%)	34 ( 37.0%)	64 ( 32.8%)
DAY 7	n	102	91	193
	No	68 ( 66.7%)	57 ( 62.6%)	125 ( 64.8%)
	Yes	34 ( 33.3%)	34 ( 37.4%)	68 ( 35.2%)
DAY 8	n	101	90	191
	No	74 ( 73.3%)	68 ( 75.6%)	142 ( 74.3%)
	Yes	27 ( 26.7%)	22 ( 24.4%)	49 ( 25.7%)
DAY 9	n	100	89	189
	No	79 ( 79.0%)	70 ( 78.7%)	149 ( 78.8%)
	Yes	21 ( 21.0%)	19 ( 21.3%)	40 ( 21.2%)

Note:

Comparisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3h - Summary of and Statistical Analysis for Presence of Headache at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	80 ( 80.0%)	68 ( 75.6%)	148 ( 77.9%)
	Yes	20 ( 20.0%)	22 ( 24.4%)	42 ( 22.1%)
DAY 11	n	98	86	184
	No	81 ( 82.7%)	70 ( 81.4%)	151 ( 82.1%)
	Yes	17 ( 17.3%)	16 ( 18.6%)	33 ( 17.9%)
DAY 12	n	99	85	184
	No	82 ( 82.8%)	73 ( 85.9%)	155 ( 84.2%)
	Yes	17 ( 17.2%)	12 ( 14.1%)	29 ( 15.8%)
DAY 13	n	98	83	181
	No	84 ( 85.7%)	74 ( 89.2%)	158 ( 87.3%)
	Yes	14 ( 14.3%)	9 ( 10.8%)	23 ( 12.7%)
DAY 14	n	95	79	174
	No	86 ( 90.5%)	69 ( 87.3%)	155 ( 89.1%)
	Yes	9 ( 9.5%)	10 ( 12.7%)	19 ( 10.9%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3h – Summary of and Statistical Analysis for Presence of Headache at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.34 (0.77; 2.35)	0.2983
Hesperidin vs Placebo at Day 7	1.19 (0.66; 2.16)	0.5611
Hesperidin vs Placebo at Day 10	1.29 (0.65; 2.58)	0.4643
Hesperidin vs Placebo at Day 14	1.38 (0.53; 3.62)	0.5063



2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3i - Summary of and Statistical Analysis for Presence of General Weakness at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	40 ( 37.4%)	32 ( 30.5%)	72 ( 34.0%)
	Yes	67 ( 62.6%)	73 ( 69.5%)	140 ( 66.0%)
DAY 2	n	106	105	211
	No	45 ( 42.5%)	35 ( 33.3%)	80 ( 37.9%)
	Yes	61 ( 57.5%)	70 ( 66.7%)	131 ( 62.1%)
DAY 3	n	103	102	205
	No	48 ( 46.6%)	39 ( 38.2%)	87 ( 42.4%)
	Yes	55 ( 53.4%)	63 ( 61.8%)	118 ( 57.6%)
DAY 4	n	103	96	199
	No	49 ( 47.6%)	37 ( 38.5%)	86 ( 43.2%)
	Yes	54 ( 52.4%)	59 ( 61.5%)	113 ( 56.8%)
DAY 5	n	102	95	197
	No	53 ( 52.0%)	41 ( 43.2%)	94 ( 47.7%)
	Yes	49 ( 48.0%)	54 ( 56.8%)	103 ( 52.3%)
DAY 6	n	103	92	195
	No	62 ( 60.2%)	47 ( 51.1%)	109 ( 55.9%)
	Yes	41 ( 39.8%)	45 ( 48.9%)	86 ( 44.1%)
DAY 7	n	102	91	193
	No	62 ( 60.8%)	52 ( 57.1%)	114 ( 59.1%)
	Yes	40 ( 39.2%)	39 ( 42.9%)	79 ( 40.9%)
DAY 8	n	101	90	191
	No	69 ( 68.3%)	56 ( 62.2%)	125 ( 65.4%)
	Yes	32 ( 31.7%)	34 ( 37.8%)	66 ( 34.6%)
DAY 9	n	100	89	189
	No	73 ( 73.0%)	62 ( 69.7%)	135 ( 71.4%)
	Yes	27 ( 27.0%)	27 ( 30.3%)	54 ( 28.6%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
 2.2 - Secondary Analysis

Table 2.2.3i - Summary of and Statistical Analysis for Presence of General Weakness at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	79 ( 79.0%)	70 ( 77.8%)	149 ( 78.4%)
	Yes	21 ( 21.0%)	20 ( 22.2%)	41 ( 21.6%)
DAY 11	n	98	86	184
	No	78 ( 79.6%)	67 ( 77.9%)	145 ( 78.8%)
	Yes	20 ( 20.4%)	19 ( 22.1%)	39 ( 21.2%)
DAY 12	n	99	85	184
	No	78 ( 78.8%)	69 ( 81.2%)	147 ( 79.9%)
	Yes	21 ( 21.2%)	16 ( 18.8%)	37 ( 20.1%)
DAY 13	n	98	83	181
	No	78 ( 79.6%)	68 ( 81.9%)	146 ( 80.7%)
	Yes	20 ( 20.4%)	15 ( 18.1%)	35 ( 19.3%)
DAY 14	n	95	79	174
	No	78 ( 82.1%)	65 ( 82.3%)	143 ( 82.2%)
	Yes	17 ( 17.9%)	14 ( 17.7%)	31 ( 17.8%)

Note:  
 Comparisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3i – Summary of and Statistical Analysis for Presence of General Weakness at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.41 (0.80; 2.47)	0.2292
Hesperidin vs Placebo at Day 7	1.16 (0.65; 2.07)	0.6097
Hesperidin vs Placebo at Day 10	1.07 (0.54; 2.16)	0.8389
Hesperidin vs Placebo at Day 14	0.99 (0.45; 2.17)	0.9764

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3j - Summary of and Statistical Analysis for Presence of Pain at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	44 ( 41.1%)	43 ( 41.0%)	87 ( 41.0%)
	Yes	63 ( 58.9%)	62 ( 59.0%)	125 ( 59.0%)
DAY 2	n	106	105	211
	No	55 ( 51.9%)	47 ( 44.8%)	102 ( 48.3%)
	Yes	51 ( 48.1%)	58 ( 55.2%)	109 ( 51.7%)
DAY 3	n	103	102	205
	No	53 ( 51.5%)	58 ( 56.9%)	111 ( 54.1%)
	Yes	50 ( 48.5%)	44 ( 43.1%)	94 ( 45.9%)
DAY 4	n	103	96	199
	No	65 ( 63.1%)	63 ( 65.6%)	128 ( 64.3%)
	Yes	38 ( 36.9%)	33 ( 34.4%)	71 ( 35.7%)
DAY 5	n	102	95	197
	No	69 ( 67.6%)	68 ( 71.6%)	137 ( 69.5%)
	Yes	33 ( 32.4%)	27 ( 28.4%)	60 ( 30.5%)
DAY 6	n	103	92	195
	No	79 ( 76.7%)	71 ( 77.2%)	150 ( 76.9%)
	Yes	24 ( 23.3%)	21 ( 22.8%)	45 ( 23.1%)
DAY 7	n	102	91	193
	No	79 ( 77.5%)	74 ( 81.3%)	153 ( 79.3%)
	Yes	23 ( 22.5%)	17 ( 18.7%)	40 ( 20.7%)
DAY 8	n	101	90	191
	No	82 ( 81.2%)	77 ( 85.6%)	159 ( 83.2%)
	Yes	19 ( 18.8%)	13 ( 14.4%)	32 ( 16.8%)
DAY 9	n	100	89	189
	No	84 ( 84.0%)	76 ( 85.4%)	160 ( 84.7%)
	Yes	16 ( 16.0%)	13 ( 14.6%)	29 ( 15.3%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis

2.2 - Secondary Analysis

Table 2.2.3j - Summary of and Statistical Analysis for Presence of Pain at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	86 ( 86.0%)	77 ( 85.6%)	163 ( 85.8%)
	Yes	14 ( 14.0%)	13 ( 14.4%)	27 ( 14.2%)
DAY 11	n	98	86	184
	No	86 ( 87.8%)	77 ( 89.5%)	163 ( 88.6%)
	Yes	12 ( 12.2%)	9 ( 10.5%)	21 ( 11.4%)
DAY 12	n	99	85	184
	No	89 ( 89.9%)	79 ( 92.9%)	168 ( 91.3%)
	Yes	10 ( 10.1%)	6 ( 7.1%)	16 ( 8.7%)
DAY 13	n	98	83	181
	No	89 ( 90.8%)	78 ( 94.0%)	167 ( 92.3%)
	Yes	9 ( 9.2%)	5 ( 6.0%)	14 ( 7.7%)
DAY 14	n	95	79	174
	No	87 ( 91.6%)	74 ( 93.7%)	161 ( 92.5%)
	Yes	8 ( 8.4%)	5 ( 6.3%)	13 ( 7.5%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3j – Summary of and Statistical Analysis for Presence of Pain at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	0.80 (0.46; 1.40)	0.4403
Hesperidin vs Placebo at Day 7	0.79 (0.39; 1.60)	0.5112
Hesperidin vs Placebo at Day 10	1.04 (0.46; 2.36)	0.9306
Hesperidin vs Placebo at Day 14	0.73 (0.23; 2.36)	0.6046

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3k - Summary of and Statistical Analysis for Presence of Irritability/Confusion at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	79 ( 73.8%)	80 ( 76.2%)	159 ( 75.0%)
	Yes	28 ( 26.2%)	25 ( 23.8%)	53 ( 25.0%)
DAY 2	n	106	105	211
	No	80 ( 75.5%)	83 ( 79.0%)	163 ( 77.3%)
	Yes	26 ( 24.5%)	22 ( 21.0%)	48 ( 22.7%)
DAY 3	n	103	102	205
	No	85 ( 82.5%)	82 ( 80.4%)	167 ( 81.5%)
	Yes	18 ( 17.5%)	20 ( 19.6%)	38 ( 18.5%)
DAY 4	n	103	96	199
	No	83 ( 80.6%)	77 ( 80.2%)	160 ( 80.4%)
	Yes	20 ( 19.4%)	19 ( 19.8%)	39 ( 19.6%)
DAY 5	n	102	95	197
	No	87 ( 85.3%)	85 ( 89.5%)	172 ( 87.3%)
	Yes	15 ( 14.7%)	10 ( 10.5%)	25 ( 12.7%)
DAY 6	n	103	92	195
	No	91 ( 88.3%)	81 ( 88.0%)	172 ( 88.2%)
	Yes	12 ( 11.7%)	11 ( 12.0%)	23 ( 11.8%)
DAY 7	n	102	91	193
	No	92 ( 90.2%)	85 ( 93.4%)	177 ( 91.7%)
	Yes	10 ( 9.8%)	6 ( 6.6%)	16 ( 8.3%)
DAY 8	n	101	90	191
	No	92 ( 91.1%)	85 ( 94.4%)	177 ( 92.7%)
	Yes	9 ( 8.9%)	5 ( 5.6%)	14 ( 7.3%)
DAY 9	n	100	89	189
	No	94 ( 94.0%)	84 ( 94.4%)	178 ( 94.2%)
	Yes	6 ( 6.0%)	5 ( 5.6%)	11 ( 5.8%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3k - Summary of and Statistical Analysis for Presence of Irritability/Confusion at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	96 ( 96.0%)	86 ( 95.6%)	182 ( 95.8%)
	Yes	4 ( 4.0%)	4 ( 4.4%)	8 ( 4.2%)
DAY 11	n	98	86	184
	No	93 ( 94.9%)	82 ( 95.3%)	175 ( 95.1%)
	Yes	5 ( 5.1%)	4 ( 4.7%)	9 ( 4.9%)
DAY 12	n	99	85	184
	No	97 ( 98.0%)	82 ( 96.5%)	179 ( 97.3%)
	Yes	2 ( 2.0%)	3 ( 3.5%)	5 ( 2.7%)
DAY 13	n	98	83	181
	No	96 ( 98.0%)	80 ( 96.4%)	176 ( 97.2%)
	Yes	2 ( 2.0%)	3 ( 3.6%)	5 ( 2.8%)
DAY 14	n	95	79	174
	No	94 ( 98.9%)	76 ( 96.2%)	170 ( 97.7%)
	Yes	1 ( 1.1%)	3 ( 3.8%)	4 ( 2.3%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.



2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3k – Summary of and Statistical Analysis for Presence of Irritability/Confusion at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.15 (0.57; 2.34)	0.6963
Hesperidin vs Placebo at Day 7	0.65 (0.22; 1.88)	0.4250
Hesperidin vs Placebo at Day 10	1.12 (0.27; 4.65)	0.8797
Hesperidin vs Placebo at Day 14	3.71 (0.37; 37.03)	0.2634

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.31 - Summary of and Statistical Analysis for Presence of Diarrhea at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	85 ( 79.4%)	82 ( 78.1%)	167 ( 78.8%)
	Yes	22 ( 20.6%)	23 ( 21.9%)	45 ( 21.2%)
DAY 2	n	106	105	211
	No	84 ( 79.2%)	83 ( 79.0%)	167 ( 79.1%)
	Yes	22 ( 20.8%)	22 ( 21.0%)	44 ( 20.9%)
DAY 3	n	103	102	205
	No	87 ( 84.5%)	80 ( 78.4%)	167 ( 81.5%)
	Yes	16 ( 15.5%)	22 ( 21.6%)	38 ( 18.5%)
DAY 4	n	103	96	199
	No	90 ( 87.4%)	72 ( 75.0%)	162 ( 81.4%)
	Yes	13 ( 12.6%)	24 ( 25.0%)	37 ( 18.6%)
DAY 5	n	102	95	197
	No	89 ( 87.3%)	76 ( 80.0%)	165 ( 83.8%)
	Yes	13 ( 12.7%)	19 ( 20.0%)	32 ( 16.2%)
DAY 6	n	103	92	195
	No	92 ( 89.3%)	72 ( 78.3%)	164 ( 84.1%)
	Yes	11 ( 10.7%)	20 ( 21.7%)	31 ( 15.9%)
DAY 7	n	102	91	193
	No	92 ( 90.2%)	76 ( 83.5%)	168 ( 87.0%)
	Yes	10 ( 9.8%)	15 ( 16.5%)	25 ( 13.0%)
DAY 8	n	101	90	191
	No	92 ( 91.1%)	77 ( 85.6%)	169 ( 88.5%)
	Yes	9 ( 8.9%)	13 ( 14.4%)	22 ( 11.5%)
DAY 9	n	100	89	189
	No	92 ( 92.0%)	81 ( 91.0%)	173 ( 91.5%)
	Yes	8 ( 8.0%)	8 ( 9.0%)	16 ( 8.5%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.31 - Summary of and Statistical Analysis for Presence of Diarrhea at Day 1 to 14, ITT population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	94 ( 94.0%)	84 ( 93.3%)	178 ( 93.7%)
	Yes	6 ( 6.0%)	6 ( 6.7%)	12 ( 6.3%)
DAY 11	n	98	86	184
	No	94 ( 95.9%)	79 ( 91.9%)	173 ( 94.0%)
	Yes	4 ( 4.1%)	7 ( 8.1%)	11 ( 6.0%)
DAY 12	n	99	85	184
	No	96 ( 97.0%)	77 ( 90.6%)	173 ( 94.0%)
	Yes	3 ( 3.0%)	8 ( 9.4%)	11 ( 6.0%)
DAY 13	n	98	83	181
	No	94 ( 95.9%)	76 ( 91.6%)	170 ( 93.9%)
	Yes	4 ( 4.1%)	7 ( 8.4%)	11 ( 6.1%)
DAY 14	n	95	79	174
	No	91 ( 95.8%)	75 ( 94.9%)	166 ( 95.4%)
	Yes	4 ( 4.2%)	4 ( 5.1%)	8 ( 4.6%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.31 – Summary of and Statistical Analysis for Presence of Diarrhea at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	1.50 (0.73; 3.06)	0.2710
Hesperidin vs Placebo at Day 7	1.82 (0.77; 4.30)	0.1748
Hesperidin vs Placebo at Day 10	1.12 (0.34; 3.63)	0.8513
Hesperidin vs Placebo at Day 14	1.21 (0.29; 5.07)	0.7906

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3m - Summary of and Statistical Analysis for Presence of Anosmia at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 1	n	107	105	212
	No	57 ( 53.3%)	62 ( 59.0%)	119 ( 56.1%)
	Yes	50 ( 46.7%)	43 ( 41.0%)	93 ( 43.9%)
DAY 2	n	106	105	211
	No	52 ( 49.1%)	56 ( 53.3%)	108 ( 51.2%)
	Yes	54 ( 50.9%)	49 ( 46.7%)	103 ( 48.8%)
DAY 3	n	103	102	205
	No	44 ( 42.7%)	50 ( 49.0%)	94 ( 45.9%)
	Yes	59 ( 57.3%)	52 ( 51.0%)	111 ( 54.1%)
DAY 4	n	103	96	199
	No	44 ( 42.7%)	48 ( 50.0%)	92 ( 46.2%)
	Yes	59 ( 57.3%)	48 ( 50.0%)	107 ( 53.8%)
DAY 5	n	102	95	197
	No	45 ( 44.1%)	45 ( 47.4%)	90 ( 45.7%)
	Yes	57 ( 55.9%)	50 ( 52.6%)	107 ( 54.3%)
DAY 6	n	103	92	195
	No	52 ( 50.5%)	43 ( 46.7%)	95 ( 48.7%)
	Yes	51 ( 49.5%)	49 ( 53.3%)	100 ( 51.3%)
DAY 7	n	102	91	193
	No	55 ( 53.9%)	48 ( 52.7%)	103 ( 53.4%)
	Yes	47 ( 46.1%)	43 ( 47.3%)	90 ( 46.6%)
DAY 8	n	101	90	191
	No	60 ( 59.4%)	50 ( 55.6%)	110 ( 57.6%)
	Yes	41 ( 40.6%)	40 ( 44.4%)	81 ( 42.4%)
DAY 9	n	100	89	189
	No	61 ( 61.0%)	51 ( 57.3%)	112 ( 59.3%)
	Yes	39 ( 39.0%)	38 ( 42.7%)	77 ( 40.7%)

Note:

Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 - Efficacy Analysis  
2.2 - Secondary Analysis

Table 2.2.3m - Summary of and Statistical Analysis for Presence of Anosmia at Day 1 to 14, ITT Population

		Placebo N=109	Hesperidin N=107	All N=216
DAY 10	n	100	90	190
	No	63 ( 63.0%)	56 ( 62.2%)	119 ( 62.6%)
	Yes	37 ( 37.0%)	34 ( 37.8%)	71 ( 37.4%)
DAY 11	n	98	86	184
	No	63 ( 64.3%)	55 ( 64.0%)	118 ( 64.1%)
	Yes	35 ( 35.7%)	31 ( 36.0%)	66 ( 35.9%)
DAY 12	n	99	85	184
	No	65 ( 65.7%)	58 ( 68.2%)	123 ( 66.8%)
	Yes	34 ( 34.3%)	27 ( 31.8%)	61 ( 33.2%)
DAY 13	n	98	83	181
	No	65 ( 66.3%)	58 ( 69.9%)	123 ( 68.0%)
	Yes	33 ( 33.7%)	25 ( 30.1%)	58 ( 32.0%)
DAY 14	n	95	79	174
	No	64 ( 67.4%)	59 ( 74.7%)	123 ( 70.7%)
	Yes	31 ( 32.6%)	20 ( 25.3%)	51 ( 29.3%)

Note:  
Comparaisons at day 3,7,10 and 14 are considered for secondary analysis. The other days are used for exploratory analysis.

2 – Efficacy Analysis

2.2 – Secondary Analysis

Table 2.2.3m – Summary of and Statistical Analysis for Presence of Anosmia at Day 1 to 14, ITT Population (continued)

Generalized linear mixed model (repeated binary logistic regression) with terms for treatment group, time and treatment group x time interaction

Contrast	OR (95% CI)	P-value
Hesperidin vs Placebo at Day 3	0.78 (0.45; 1.35)	0.3686
Hesperidin vs Placebo at Day 7	1.05 (0.59; 1.86)	0.8711
Hesperidin vs Placebo at Day 10	1.03 (0.57; 1.87)	0.9124
Hesperidin vs Placebo at Day 14	0.70 (0.36; 1.37)	0.2952